Prices are updated after-hours
  Neurological

nasdaq:ATHX Athersys, Inc.

ATHX | $0.1018 -40.86% 95M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-87.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (46.93% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 2,290,644
http://www.athersys.com
 Sec Filling | Patents | 83 employees


(US) Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
cardiovascular   stem cell   urea   t-cell   neurological   ceiling  

add to watch list Paper trade email alert is off

nasdaq:FWP Forward Pharma A/S

FWP | $1.95 7.74% 7.18% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-64.55% volume)
Earnings Calendar:
Market Cap: $ 13,827,811
http://www.forward-pharma.com
 Sec Filling | Patents | 5 employees


(DK) Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 1, 2005 and is headquartered in Copenhagen, Denmark.
neurological   treatment  

add to watch list Paper trade email alert is off

nasdaq:NTUS Natus Medical Incorporated

NTUS | $32.96 0.09% 0.0% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-08-04
Market Cap: $ 1,139,798,659
http://www.natus.com
 Sec Filling | Patents | 1484 employees


Natus Medical, Inc. provides medical device solutions focuses on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Its products are used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, sleep disorders, neuromuscular diseases and balance and mobility disorders. The company was founded by Maurizio Liverani, John Robert Camber Porter, William New, Jr., Brian Prinn and William W. Moore on May 26, 1987 and is headquartered in Pleasanton, CA.
diagnostics   neurological   treatment  

add to watch list Paper trade email alert is off

nasdaq:SIOX Sio Gene Therapies Inc

SIOX | $0.478 -20.5% 40K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (14.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (84.8% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 35,360,144
http://www.siogtx.com
 Sec Filling | Patents | 38 employees


(United Kingdom) Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in New York, NY.
acquisitions   gene therapies   parkinson   neurological  

add to watch list Paper trade email alert is off

nyse:NVTA Invitae Corporation

NVTA | News | $0.019 0.0% 22M twitter stocktwits trandingview |
Health Services
(0.0% 1d) (0.0% 1m) (-98.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (127.23% volume)
Earnings Calendar:
Market Cap: $ 5,443,364
http://www.invitae.com
 Sec Filling | Patents | 1300 employees


(US) Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.
cancer   cardiology   genetic   neurological  

add to watch list Paper trade email alert is off

nyse:EHC Encompass Health Corporation

EHC 4 | $82.78 0.39% 610K twitter stocktwits trandingview |
Health Services
(0.0% 1d) (8.3% 1m) (30.2% 1y) (0.0% 2d) (2.7% 3d) (4.1% 7d) (12.26% volume)
Earnings Calendar: 2024-02-07
Market Cap: $ 8,289,591,766
http://www.encompasshealth.com
 Sec Filling | Patents | 31570 employees


(US) Encompass Health Corp. engages in providing post-acute healthcare services. It operates through the following segments: Inpatient Rehabilitation and Home Health & Hospice. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provides rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac & pulmonary conditions, brain & spinal cord injuries, complex orthopedic conditions and amputations. The Home Health and Hospice segment provides Medicare-certified home nursing, specialized home care and in-home services. The company was founded by Richard M. Scrushy on February 22, 1984 and is headquartered in Birmingham, AL.
spinal cord   neurological   treatment   als  

add to watch list Paper trade email alert is off

nasdaq:HRMY Harmony Biosciences Holdings, Inc.

HRMY | $29.18 1.14% 180K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-11.5% 1m) (-9.2% 1y) (0.0% 2d) (-1.7% 3d) (-1.9% 7d) (42.27% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 1,657,167,625
https://harmonybiosciences.com
 Sec Filling | Patents | 200 employees


Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
neurological   treatment  

add to watch list Paper trade email alert is off

nasdaq:HSDT Helius Medical Technologies, Inc.

HSDT | $4.98 7.4K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-12.5% 1m) (-47.4% 1y) (0.0% 2d) (-2.0% 3d) (-3.1% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 4,418,729
http://www.heliusmedical.com
 Sec Filling | Patents | 19 employees


Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.
education   neurological  

add to watch list Paper trade email alert is off

nasdaq:SUPN Supernus Pharmaceuticals, Inc.

SUPN | $30.23 0.94% 95K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-8.5% 1m) (-19.9% 1y) (0.0% 2d) (0.8% 3d) (3.7% 7d) (-42.92% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,654,637,720
http://www.supernus.com
 Sec Filling | Patents | 464 employees


(US) Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
nervous system   neurological   treatment   3d  

Drugs
OXTELLAR XR (OXCARBAZEPINE)
Trokendi XR (topiramate)

add to watch list Paper trade email alert is off

nasdaq:TRVI Trevi Therapeutics, Inc.

TRVI | $2.68 -5.97% 62K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-14.9% 1m) (-2.7% 1y) (0.0% 2d) (-3.1% 3d) (5.9% 7d) (-11.62% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 184,813,248
http://www.trevitherapeutics.com
 Sec Filling | Patents | 17 employees


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
chronic cough   fibrosis   parkinson   neurological   treatment  

add to watch list Paper trade email alert is off

nyse:USPH U.S. Physical Therapy, Inc.

USPH 4 | $103.51 0.12% 29K twitter stocktwits trandingview |
Health Services
(0.0% 1d) (-6.1% 1m) (-1.5% 1y) (0.0% 2d) (3.5% 3d) (4.3% 7d) (14.61% volume)
Earnings Calendar:
Market Cap: $ 1,559,697,478
http://www.usph.com
 Sec Filling | Patents | 5400 employees


(US) U.S. Physical Therapy, Inc. operates outpatient physical therapy clinics, which provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries. The company was founded in 1990 and is headquartered in Houston, TX.
neurological   treatment  

add to watch list Paper trade email alert is off

nasdaq:VRTX Vertex Pharmaceuticals Incorporated

VRTX | $401.58 -0.82% 430K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-2.7% 1m) (22.0% 1y) (0.0% 2d) (1.8% 3d) (2.5% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-05
Market Cap: $ 103,792,102,962
http://www.vrtx.com
 Sec Filling | Patents | 3000 employees


(US) Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
sclerosis   cancer   battery   batteries   autoimmunity   infectious disease   multiple sclerosis   rheumatoid arthritis   influenza   fibrosis   molecule drugs   neurological   treatment   injection  

Drugs
Kalydeco (ivacaftor)
ORKAMBI (lumacaftor and ivacaftor)
SYMDEKO (Tezacaftor and Ivacaftor)
Trikafta (Elexacaftor, Tezacaftor, and Ivacaftor)

add to watch list Paper trade email alert is off

nasdaq:XCUR Exicure, Inc.

XCUR 4 | $0.511 -5.42% 18K twitter stocktwits trandingview |
Commercial Services
(0.0% 1d) (-14.1% 1m) (-41.0% 1y) (0.0% 2d) (0.0% 3d) (-6.9% 7d) (-64.99% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 4,419,285
http://www.exicuretx.com
 Sec Filling | Patents | 63 employees


(US) Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
genetic   neurological   treatment  

add to watch list Paper trade email alert is off

nasdaq:XENE Xenon Pharmaceuticals Inc.

XENE | $39.61 -3.6% 150K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-3.8% 1m) (3.3% 1y) (0.0% 2d) (2.7% 3d) (3.0% 7d) (-18.13% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 2,987,880,612
http://www.xenon-pharma.com
 Sec Filling | Patents | 104 employees


(CA) Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
nervous system   neurological  

add to watch list Paper trade email alert is off

nyse:ABBV AbbVie Inc.

ABBV | News | $168.055 -0.88% 1.8M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-5.0% 1m) (2.8% 1y) (0.0% 2d) (1.0% 3d) (2.7% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 297,566,078,728
http://www.abbvie.com
 Sec Filling | Patents | 30000 employees


AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
cancer   hiv   autoimmunity   hepatitis   fibrosis   metabolic   parkinson   neurological  

Drugs
Alcohol - Hand Sanitizer (Alcohol)
Androgel (Testosterone)
Creon (Pancrelipase)
Depakote (Divalproex Sodium)
Depakote ER (Divalproex Sodium)
Depakote Sprinkles (Divalproex Sodium)
Duopa (Carbidopa and Levodopa)
Gengraf (Cyclosporine)
Humira (Adalimumab)
Kaletra (Lopinavir and Ritonavir)
K-Tab (Potassium Chloride)
Lupaneta Pack (leuprolide acetate and norethindrone acetate)
Lupron Depot (leuprolide acetate)
Lupron Depot-PED (leuprolide acetate)
Marinol (Dronabinol)
Mavyret (Glecaprevir and Pibrentasvir)
Niaspan (Niacin)
Nimbex (Cisatracurium besylate)
Norvir (Ritonavir)
Oriahnn (Elagolix and Estradiol and Norethisterone)
Orilissa (Elagolix)
Rinvoq (Upadacitinib)
Skyrizi (Risankizumab-rzaa)
Survanta (Beractant)
Synthroid (Levothyroxine Sodium)
Tarka (Trandolapril and Verapamil Hydrochloride)
Tricor (Fenofibrate)
Trilipix (Fenofibric Acid)
Ultane (Sevoflurane)
Venclexta (Venetoclax)
Viekira Pak (Dasabuvir and Ombitasvir and Paritaprevir and Ritonavir)
Zemplar (Paricalcitol)

add to watch list Paper trade email alert is off

nyse:BHVN Biohaven Pharmaceutical Holding Company Ltd.

BHVN | News 0 d | $39.05 -1.41% 570K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-28.3% 1m) (195.4% 1y) (0.0% 2d) (3.3% 3d) (-6.0% 7d) (84.34% volume)
Earnings Calendar:
Market Cap: $ 3,446,492,121
http://www.biohavenpharma.com
 Sec Filling | Patents | 647 employees


(US) Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.
neurological  

add to watch list Paper trade email alert is off

nasdaq:APM Aptorum Group Limited

APM | $5.69 3.45% 12K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-29.2% 1m) (98.5% 1y) (0.0% 2d) (-2.8% 3d) (-4.3% 7d) (77.71% volume)
Earnings Calendar:
Market Cap: $ 9,784,080
http://www.aptorumgroup.com
 Sec Filling | Patents | 37 employees


Aptorum Group Ltd. is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, metabolic disorders, women's health and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; operates the activities of AML Clinic; and sale of natural supplement. The firm’s pipe line is enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets. It also has projects focused on natural supplement for women undergoing menopause and experiencing related symptoms. The company was founded by Ian Huen on September 13, 2010 and is headquartered in London, the United Kingdom.
cancer   infectious disease   surgical robotics   urea   women health   drug discovery   metabolic   women   diagnostics   neurological   treatment  

add to watch list Paper trade email alert is off

nasdaq:BIIB Biogen Inc.

BIIB | $199.93 3.49% 2.2M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-10.8% 1m) (-31.6% 1y) (0.0% 2d) (-0.5% 3d) (-0.6% 7d) (30.56% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 29,061,984,344
http://www.biogen.com
 Sec Filling | Patents | 7400 employees


(US) Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
sclerosis   neurodegenerative   multiple sclerosis   neurological   treatment  

Drugs
ALPROLIX (Coagulation Factor IX (Recombinant), Fc Fusion Protein)
AVONEX (interferon beta-1a)
Plegridy (peginterferon beta-1a)
Plegridy Pen (peginterferon beta-1a)
Spinraza (Nusinersen)
Tecfidera (dimethyl fumarate)
TECFIDERA (dimethyl fumarate)
TYSABRI (natalizumab)
Vumerity (diroximel fumarate)

add to watch list Paper trade email alert is off

nasdaq:CPRX Catalyst Pharmaceuticals, Inc.

CPRX | News | $15.085 2.41% 550K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-7.1% 1m) (-8.5% 1y) (0.0% 2d) (-2.5% 3d) (-3.5% 7d) (-2.29% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 1,780,197,323
http://www.catalystpharma.com
 Sec Filling | Patents | 76 employees


(US) Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
antibody   neurological  

Drugs
Firdapse (amifampridine phosphate)

add to watch list Paper trade email alert is off

nasdaq:ADXN Addex Therapeutics Ltd

ADXN | $18.74 9K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (58.9% 1m) (24.9% 1y) (0.0% 2d) (-2.8% 3d) (-13.6% 7d) (99.02% volume)
Earnings Calendar:
Market Cap: $ 28,790,018
http://www.addextherapeutics.com
 Sec Filling | Patents | 63 employees


(CH) Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
neurological  

add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlist
Gainers vs Losers
58% 42%

Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M twitter stocktwits trandingview |
Consumer Services
CZOO | $11.04 121.24% 11M twitter stocktwits trandingview |

LICN | $0.9107 62.63% 14M twitter stocktwits trandingview |

BOF | $1.87 59.83% 100M twitter stocktwits trandingview |

AMST | $3.18 59.0% 67M twitter stocktwits trandingview |
Technology Services
SKIL 4 | $8.72 52.72% 410K twitter stocktwits trandingview |
Information
MTC | $3.31 47.77% 7.7M twitter stocktwits trandingview |
Technology Services
MULN | News | $3.915 43.41% 12M twitter stocktwits trandingview |
Information
WIMI | $1.04 43.37% 17M twitter stocktwits trandingview |
Technology Services
RILY | $29.755 36.99% 12M twitter stocktwits trandingview |
Finance
Last 48 Hours Insiders Buying
WABC | $47.5 -0.54% 24K twitter stocktwits trandingview |
Finance
 | 19:30
NWFL | News | $24.0 -0.46% 4.9K twitter stocktwits trandingview |
Finance
 | 17:00
MNSB P 310 | $15.82 -3.3% 21K twitter stocktwits trandingview |
Finance
 | 15:30
TPL P 3 | $585.42 -0.41% 31K twitter stocktwits trandingview |
Miscellaneous
 | 15:01
ISBA P 966 | $18.0001 3.1K twitter stocktwits trandingview |
Finance and Insurance
 | 15:01
MEGI | $12.05 0.58% 120K twitter stocktwits trandingview |
| 00:30
CTRN P 29000 | $21.95 -1.26% 33K twitter stocktwits trandingview |
Retail Trade
 | 22:00
CONN | $3.74 1.08% 27K twitter stocktwits trandingview |
Retail Trade
 | 21:30
TGEN P 6000 | $0.685 6.6K twitter stocktwits trandingview |
Utilities
 | 18:30
CMTV P 700 | $16.59 1K twitter stocktwits trandingview |
Finance and Insurance
 | 18:30
FNB | $13.595 -0.26% 1.1M twitter stocktwits trandingview |
Finance
 | 17:30
RMCF | $3.54 7.1K twitter stocktwits trandingview |
Consumer Non-Durables
 | 20:10
12 months watchlist earnings calendar